Review of Comparative Effectiveness of Treatments to Prevent Fractures
Authors: Lionel S. Lim
Journal: Annals of Internal Medicine (2008)

Letters3 June 2008Review of Comparative Effectiveness of Treatments to Prevent FracturesLionel S. Lim, MD, MPHLionel S. Lim, MD, MPHFrom Griffin Hospital, Derby, CT 06418.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-148-11-200806030-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:MacLean and colleagues did not mention musculoskeletal adverse effects associated with bisphosphonates in their review of osteoporosis treatments (1). Although most adverse effects are gastrointestinal, bisphosphonate use may also induce musculoskeletal side effects. Postmarketing reports describe severe disabling and incapacitating musculoskeletal pain, which may occur up to 4 years after taking alendronate or risedronate (2).Retrospective cohort studies have examined the prevalence of musculoskeletal adverse effects of alendronate and risedronate (3, 4). Among 840 patients receiving either of these bisphosphonates (84.5% received alendronate), the prevalence of musculoskeletal adverse effects (bone pain, arthralgia, and myalgia) was 2.3% for ...References1. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213. [PMID: 18087050] LinkGoogle Scholar2. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain [Letter]. Arch Intern Med. 2005;165:346-7. [PMID: 15710802] MedlineGoogle Scholar3. Anastasilakis AD, Goulis DG, Kita M, Avramidis A. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. Hormones (Athens). 2007;6:233-41. [PMID: 17724008] MedlineGoogle Scholar4. Bock O, Boerst H, Thomasius FE, Degner C, Stephan-Oelkers M, Valentine SM, et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact. 2007;7:144-8. [PMID: 17627083] MedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Griffin Hospital, Derby, CT 06418.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSystematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Catherine MacLean , Sydne Newberry , Margaret Maglione , Maureen McMahon , Veena Ranganath , Marika Suttorp , Walter Mojica , Martha Timmer , Alicia Alexander , Melissa McNamara , Sheetal B. Desai , Annie Zhou , Susan Chen , Jason Carter , Carlo Tringale , Di Valentine , Breanne Johnsen , and Jennifer Grossman Review of Comparative Effectiveness of Treatments to Prevent Fractures John L. Stock , John L. Mershon , and Michael Jay Schoenfeld Review of Comparative Effectiveness of Treatments to Prevent Fractures Dennis M. Black , Steven Boonen , Pierre Delmas , and Kenneth W. Lyles Review of Comparative Effectiveness of Treatments to Prevent Fractures Robert Karis Review of Comparative Effectiveness of Treatments to Prevent Fractures Catherine MacLean , Margaret Maglione , and Marika Suttorp Review of Comparative Effectiveness of Treatments to Prevent Fractures Harold Rosen Metrics 3 June 2008Volume 148, Issue 11Page: 884-885KeywordsArthralgiaBoneCohort studiesConflicts of interestLower back painMyalgiaOsteoporosis ePublished: 3 June 2008 Issue Published: 3 June 2008 CopyrightCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...